Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387881
Status:
COMPLETED
Last Update Posted:
2016-12-16
First Post:
2006-10-11
Brief Title:
TREXIMET Formerly Known as TREXIMA for the Acute Treatment of Probable Migraine ICHD-II 161
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA Sumatriptan SuccinateNaproxen Sodium for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura ICHD-II 161 TREXIMET
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to determine the efficacy and tolerability of TREXIMET formerly known as TREXIMA compared to placebo for the acute treatment of probable migraine a sub-type of migraine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None